Compare Sana Biotechnology Inc (SANA) vs Wynn Resorts, Limited (WYNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Wynn Resorts, Limited — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Wynn Resorts, Limited trades at $102.77 (market cap $10.79B). The key difference: Wynn Resorts, Limited is far larger — about 9.5× Sana Biotechnology Inc's market cap, and Wynn Resorts, Limited pays a 0.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | WYNN | |
|---|---|---|
Market Cap | $1.13B | $10.79B |
Sector | Health | Consumer Cyclical |
52-Week High | $5.92 | $133.34 |
52-Week Low | $2.68 | $94.37 |
Enterprise Value | $1.05B | $21.03B |
Dividend Yield | — | 0.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Wynn Resorts (WYNN) trades at $103.51, up 0.99% today, showing steady recovery from pandemic lows. The stock maintains bullish technical signals with strong institutional support, though faces headwinds from high debt levels and margin pressure. Recent Q2 2026 earnings beat expectations with $1.24 EPS versus $0.99 estimate, driven by Macau strength, while Las Vegas operations show slower growth. Analyst consensus remains strongly bullish with 64% buy ratings and $133 price target, representing 28% upside potential.
Investment outlook balances growth potential against significant risks. The company's Macau recovery and UAE expansion provide growth catalysts, but high leverage ($10.5B debt) and rising capex for Wynn Al Marjan project create cash flow pressure. Current valuation at 25x P/E appears reasonable given recovery trajectory, but investors should monitor margin trends and capital expenditure discipline closely given the negative shareholder equity position.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Wynn Resorts, Limited
Wynn Resorts operates luxury casinos and resorts. The company was founded in 2002 by Steve Wynn, the former CEO. The company operates four megaresorts: Wynn Macau and Encore in Macao and Wynn Las Vegas and Encore in Las Vegas. Cotai Palace opened in August 2016 in Macao, Encore Boston Harbor in Massachusetts opened June 2019. Additionally, we expect the company to begin construction on a new building next to its existing Macao Palace resort in 2023, which we forecast to open in 2026. The company also operates Wynn Interactive, a digital sports betting and iGaming platform. The company received 76% and 24% of its 2019 prepandemic EBITDA from Macao and Las Vegas, respectively.
Read more on WYNN →
